19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
13:23 , May 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Blindness Mouse studies suggest inhibiting MEF2D could help treat light-induced retinal degeneration. In retinal tissue samples from a mouse model of the disease, the MEF2D inhibitor tool compound carnosic acid decreased cell death and increased...
20:01 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); B cell lymphoma Patient sample, cell culture and mouse studies suggest HDAC inhibitors could help treat patients with B cell precursor ALL expressing gene fusions involving MEF2D. Levels of HDAC9 in...
07:00 , Sep 6, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Myocyte enhancer factor 2D (MEF2D) Mouse studies suggest activating the transcription factor MEF2D with...